Registry-listed formulations

Cholic Acid · chembl:CHEMBL205596

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

2 source entries across 2 studies. This list may not include all unresolved or historical entries.

  • CholbamRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • CHOLIC ACIDRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: CAPSULE, HARD

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source

Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(17%)
Results Posted
100%(4 trials)
Terminated
1(17%)

Phase Distribution

Phase 2
1
17%
Not Applicable
1
17%
Phase 1/2
1
17%
Phase 3
2
33%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1/2Combined phases
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 1/21 (20.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)
N/A1 (20.0%)

Trials by Status

terminated117%
completed467%
active_not_recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
active_not_recruiting

The REPLACE Registry for Cholbam® (Cholic Acid)

NCT03115086
completedphase_2

Cholic Acid for Hepatic Steatosis in Lipodystrophy

NCT00457639
completedphase_1_2

Smith-Lemli-Opitz Syndrome and Cholic Acid

NCT03720990
completedphase_3

Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis

NCT01115582
completedphase_3

Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis

NCT01438411
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03115086

The REPLACE Registry for Cholbam® (Cholic Acid)

Active Not Recruiting
NCT00457639Phase 2

Cholic Acid for Hepatic Steatosis in Lipodystrophy

Completed
NCT03720990Phase 1/2

Smith-Lemli-Opitz Syndrome and Cholic Acid

Completed
NCT01115582Phase 3

Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis

Completed
NCT01438411Phase 3

Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis

Completed
NCT00004442Not Applicable

Study of Bile Acids in Patients With Peroxisomal Disorders

Terminated

All 6 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
6

External References

ChEMBL
CHEMBL205596

Names & Codes

Trade Names

cholbam

ATC Classification

A05AA03

Research Codes

E1000NSC-6135